GlassScriptPhysician profile
Paul Dimarco
NPI 1265479463
$1,086.15
in general payments reported to CMS, 2019-2025
21 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $145 · 2021: $95.13 · 2022: $53.58 · 2023: $91.24 · 2024: $213 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $119.99 | 2019-2024 | Freestyle Libre 2 |
| Novo Nordisk INC | $111.28 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $104.22 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $97.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $96.25 | 2019-2024 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.41 | 2019-2025 | Jardiance |
| Sequel Med Tech, LLC | $58.07 | 2025 | Twiist |
| Amgen INC. | $45.28 | 2019 | |
| Beta Bionics, INC. | $43.65 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $41.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.42 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $40.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $37.70 | 2021-2022 | |
| Insulet Corporation | $35.23 | 2020 | |
| Philips North America LLC | $32.12 | 2024 | (Ck7) Extended Holter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $28.72 | 2024 | Crysvita |
| Dexcom, INC. | $21.62 | 2023 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $20.60 | 2024 | |
| Nevro Corp. | $18.80 | 2024 | Senza |
| Mannkind Corporation | $16.91 | 2022 | |
| Ascendis Pharma Endocrinology INC | $15.00 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dimarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.